title: [Pharmacotherapy of patients with the borderline personality disorders].
abstract: The American Psychiatric Association (APA) provides guidelines in which it recommends applying pharmacotherapy in order to take under control the symptoms developing in the period of acute decompensation, as well as those connected with the susceptibility of an afflicted individual to an injury resulting from the basic disorder, The guidelines of the APA include in particular what follows: in case of affective deregulation, administering anti-depressive drugs (LDP), mainly SSRLs, as well as IMAOs; in order to take under control the disorders of impulsive-behavioural control, administering SSRIs and normothymic drugs, whilst in the treatment of infirm with perceptive-cognitive disorders, administering antipsychotic medicines (LPP). Currently, upon the basis of existing evidence, one may claim that in the treatment of the borderline personality disorders, psychotherapy is much more effective than pharmacology An obstacle on the road to make psychotherapy more widespread is relatively high cost, which is connected with the necessity of remunerating highly-qualified psychotherapists, involved in the work with the infirm, suffering from the borderline personality disorders, and the time, needed to conduct a successful psychotherapy, as well as the phenomenon of the premature discontinuation of therapy by patients who are emotionally unstable. In turn, pharmacotherapy seems to be necessary in the period of more acute disorders, i.e. in the states of increased affective lability, in dysphoric states, in impulsive behaviours and in the periods of the occurrence of pseudo-psychotic symptoms.
authors.affiliation: Katedra Psychiatrii Collegium Medicum w Bydgoszczy. maxeve@interia.pl
authors.forename: Ewa
authors.initials: E
authors.lastname: Ogłodek
authors.forename: Aleksander
authors.initials: A
authors.lastname: Araszkiewicz
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001883:Borderline Personality Disorder / Q000188:drug therapy*; D006801:Humans; D011613:Psychotherapy
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents